Professor Mike Cork is one of the lead authors and the only UK based author of a recent paper in the New England Journal of Medicine on the treatment of severe atopic dermatitis. He and colleagues reported the successful outcome of two phase III trials using a human monoclonal antibody against interleukin-4 receptor alpha to block the actions of type 2 cytokines.
This research will revolutionise the treatment options for patients with this severe skin condition. The Clinical Research Facility at the University of Sheffield was actively involved in these studies.
The doi for the article is: 10.1056/NEJMoa1610020